Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Form 144 Notice of Proposed Sale filed for Doximity (NYSE: DOCS) indicates an insider sale transaction. Timothy Cabral plans to sell 10,000 shares of common stock with an aggregate market value of $600,000, to be executed through Morgan Stanley Smith Barney LLC.
Key transaction details:
- Securities were acquired through stock option exercise on June 25, 2025
- Sale represents a small fraction of total outstanding shares (187,826,153)
- Planned execution date: June 25, 2025
- Previous sale by the same insider: 10,000 shares sold on May 23, 2025 for $505,796
This Form 144 filing represents a declaration of intent to sell securities and confirms the seller has no knowledge of undisclosed material adverse information regarding Doximity's operations.
The Form 144 filing submitted on behalf of Doximity, Inc. (DOCS) discloses a proposed sale of 10,000 common shares through broker Morgan Stanley Smith Barney LLC. The shares—acquired via a stock-option exercise on 06/25/2025—carry an aggregate market value of $600,000. With 187,826,153 shares outstanding, the transaction represents roughly 0.005 % of total shares, indicating an immaterial dilution impact. The seller reported no prior sales in the last three months and affirmed awareness of no undisclosed adverse information. The planned sale is scheduled for on or after 06/25/2025 on the NYSE under Rule 144, reflecting routine insider liquidity while complying with SEC disclosure requirements.